Syncore Biotechnology Co Stock Price To Sales
| 4192 Stock | TWD 35.85 0.50 1.38% |
SynCore Biotechnology Co fundamentals help investors to digest information that contributes to SynCore Biotechnology's financial success or failures. It also enables traders to predict the movement of SynCore Stock. The fundamental analysis module provides a way to measure SynCore Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SynCore Biotechnology stock.
SynCore |
SynCore Biotechnology Co Company Price To Sales Analysis
SynCore Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current SynCore Biotechnology Price To Sales | 221.58 X |
Most of SynCore Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SynCore Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, SynCore Biotechnology Co has a Price To Sales of 221 times. This is much higher than that of the Healthcare sector and 125.16% higher than that of the Biotechnology industry. The price to sales for all Taiwan stocks is notably lower than that of the firm.
SynCore Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SynCore Biotechnology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SynCore Biotechnology could also be used in its relative valuation, which is a method of valuing SynCore Biotechnology by comparing valuation metrics of similar companies.SynCore Biotechnology is currently under evaluation in price to sales category among its peers.
SynCore Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (13.97) % | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.08 M | |||
| Shares Owned By Insiders | 66.92 % | |||
| Price To Book | 9.34 X | |||
| Price To Sales | 221.58 X | |||
| Revenue | 6.94 M | |||
| Gross Profit | 2.97 M | |||
| EBITDA | (404.13 M) | |||
| Net Income | (458.6 M) | |||
| Cash And Equivalents | 380.81 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 61.11 M | |||
| Debt To Equity | 9.40 % | |||
| Current Ratio | 5.04 X | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (229.86 M) | |||
| Earnings Per Share | (3.73) X | |||
| Number Of Employees | 65 | |||
| Beta | 1.14 | |||
| Market Capitalization | 2.88 B | |||
| Total Asset | 824.44 M | |||
| Z Score | 28.2 | |||
| Net Asset | 824.44 M |
About SynCore Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SynCore Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SynCore Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SynCore Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with SynCore Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SynCore Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with SynCore Stock
| 0.62 | 4743 | Oneness Biotech | PairCorr |
| 0.74 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.68 | 4174 | OBI Pharma | PairCorr |
Moving against SynCore Stock
| 0.7 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.68 | 0057 | Fubon MSCI Taiwan | PairCorr |
| 0.66 | 3257 | Champion Microelectronic | PairCorr |
| 0.59 | 4162 | PharmaEngine | PairCorr |
| 0.58 | 6674 | Compal Broadband Networks | PairCorr |
The ability to find closely correlated positions to SynCore Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SynCore Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SynCore Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SynCore Biotechnology Co to buy it.
The correlation of SynCore Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SynCore Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SynCore Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SynCore Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.